Can a Real-World study reveal the staying power of guselkumab?
NCT ID NCT07746765
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This observational study tracks how long patients with moderate-to-severe Crohn's disease or ulcerative colitis continue taking guselkumab, a biologic treatment, in everyday clinical practice. Researchers will measure time until treatment discontinuation and early responses like bowel urgency. The goal is to understand real-world persistence and inform treatment decisions for inflammatory bowel disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guselkumab
- What this could lead to
- If successful, this study could reveal how long patients typically stay on guselkumab, helping doctors and patients make more informed treatment decisions for inflammatory bowel disease.
- What could go wrong
- This is a small observational study, so results may not apply broadly. It does not test new effects of the drug, and persistence may vary due to factors not fully captured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.